Psychomotor agitation and hyperactive delirium in COVID-19 patients treated with aripiprazole 9.75 mg/1.3 ml immediate release.
作者信息
Martinotti Giovanni, Barlati Stefano, Prestia Davide, Palumbo Claudia, Giordani Matteo, Cuomo Alessandro, Miuli Andrea, Paladini Carlo, Amore Mario, Bondi Emi, Vita Antonio, Fagiolini Andrea, Di Giannantonio Massimo
机构信息
Department of Neuroscience, Imaging, Clinical Sciences, University G. d'Annunzio, Chieti-Pescara, Italy.
Department of Pharmacy, Pharmacology, Clinical Sciences, University of Hertfordshire, Herts, UK.
出版信息
Psychopharmacology (Berl). 2020 Nov;237(11):3497-3501. doi: 10.1007/s00213-020-05644-3. Epub 2020 Aug 21.
Abstract
摘要
相似文献
1
Psychomotor agitation and hyperactive delirium in COVID-19 patients treated with aripiprazole 9.75 mg/1.3 ml immediate release.
Psychopharmacology (Berl). 2020 Nov;237(11):3497-3501. doi: 10.1007/s00213-020-05644-3. Epub 2020 Aug 21.
2
Risk factors for agitation and hyperactive delirium in adult postcardiotomy patients with extracorporeal membrane oxygenation support: an observational study.
Perfusion. 2020 Sep;35(6):534-542. doi: 10.1177/0267659120937549. Epub 2020 Jul 4.
3
Hyperactive Delirium with Severe Agitation.
Emerg Med Clin North Am. 2024 Feb;42(1):41-52. doi: 10.1016/j.emc.2023.06.011. Epub 2023 Sep 21.
4
Understanding the decision-making of critical care nurses when restraining a patient with psychomotor agitation secondary to hyperactive delirium: A 'Think Aloud' study.
J Clin Nurs. 2022 Jan;31(1-2):121-133. doi: 10.1111/jocn.15889. Epub 2021 May 30.
5
Managing agitation secondary to hyperactive delirium in deteriorating patients.
Nurs Stand. 2022 Jan 5;37(1):46-50. doi: 10.7748/ns.2021.e11730. Epub 2021 Nov 8.
6
Predictive factors for agitation severity of hyperactive delirium in terminally ill cancer patients in a general hospital using ordered logistic regression analysis.
J Palliat Med. 2013 Sep;16(9):1020-5. doi: 10.1089/jpm.2013.0100. Epub 2013 Jul 26.
7
Rate and risk factors for a hyperactivity delirium in patients with aneurysmal subarachnoid haemorrhage.
Neurosurg Rev. 2019 Jun;42(2):481-488. doi: 10.1007/s10143-018-0990-9. Epub 2018 Jun 9.
8
Dexmedetomidine versus haloperidol for sedation of non-intubated patients with hyperactive delirium during the night in a high dependency unit: study protocol for an open-label, parallel-group, randomized controlled trial (DEX-HD trial).
BMC Anesthesiol. 2023 Jun 3;23(1):193. doi: 10.1186/s12871-023-02158-1.
9
Association of Hypoactive and Hyperactive Delirium With Cognitive Function After Critical Illness.
Crit Care Med. 2020 Jun;48(6):e480-e488. doi: 10.1097/CCM.0000000000004313.
10
An open trial of aripiprazole for the treatment of delirium in hospitalized cancer patients.
Palliat Support Care. 2011 Dec;9(4):351-7. doi: 10.1017/S1478951511000368.
引用本文的文献
1
Persistent Neurological Deficits in Mouse PASC Reveal Antiviral Drug Limitations.
bioRxiv. 2024 Jun 3:2024.06.02.596989. doi: 10.1101/2024.06.02.596989.
2
Delirium and other neuropsychiatric manifestations of COVID-19 infection in people with preexisting psychiatric disorders: a systematic review.
J Med Case Rep. 2021 Dec 13;15(1):586. doi: 10.1186/s13256-021-03140-6.
3
Predictors of Acute Encephalopathy in Patients with COVID-19.
J Clin Med. 2021 Oct 20;10(21):4821. doi: 10.3390/jcm10214821.
4
Delirium in COVID-19 patients: a multicentric observational study in Italy.
Neurol Sci. 2021 Oct;42(10):3981-3988. doi: 10.1007/s10072-021-05461-2. Epub 2021 Jul 28.
5
A rapid review of the pathoetiology, presentation, and management of delirium in adults with COVID-19.
J Psychosom Res. 2021 Feb;141:110350. doi: 10.1016/j.jpsychores.2020.110350. Epub 2020 Dec 25.
6
Antioxidant Properties of Second-Generation Antipsychotics: Focus on Microglia.
Pharmaceuticals (Basel). 2020 Dec 12;13(12):457. doi: 10.3390/ph13120457.
7
COVID-19-Associated Guillain-Barre Syndrome: Atypical Para-infectious Profile, Symptom Overlap, and Increased Risk of Severe Neurological Complications.
SN Compr Clin Med. 2020;2(12):2702-2714. doi: 10.1007/s42399-020-00646-w. Epub 2020 Nov 21.
本文引用的文献
1
[The keypoints in treatment of the critical coronavirus disease 2019 patient(2)].
Zhonghua Jie He He Hu Xi Za Zhi. 2020 Apr 12;43(4):277-281. doi: 10.3760/cma.j.cn112147-20200224-00159.
2
Patients with mental health disorders in the COVID-19 epidemic.
Lancet Psychiatry. 2020 Apr;7(4):e21. doi: 10.1016/S2215-0366(20)30090-0.
3
Human Coronaviruses and Other Respiratory Viruses: Underestimated Opportunistic Pathogens of the Central Nervous System?
Viruses. 2019 Dec 20;12(1):14. doi: 10.3390/v12010014.
4
Delirium in Hospitalized Older Adults.
N Engl J Med. 2018 Jan 4;378(1):96-97. doi: 10.1056/NEJMc1714932.
5
Neurological Complications of Middle East Respiratory Syndrome Coronavirus: A Report of Two Cases and Review of the Literature.
Case Rep Neurol Med. 2016;2016:3502683. doi: 10.1155/2016/3502683. Epub 2016 Apr 28.
6
Aripiprazole.
Am J Hosp Palliat Care. 2017 Mar;34(2):180-185. doi: 10.1177/1049909115612800. Epub 2016 Jul 10.
7
Clinical pharmacokinetics of antiretroviral drugs in older persons.
Expert Opin Drug Metab Toxicol. 2013 May;9(5):573-88. doi: 10.1517/17425255.2013.781153. Epub 2013 Mar 20.
8
Vulnerability: the crossroads of frailty and delirium.
J Am Geriatr Soc. 2011 Nov;59 Suppl 2(Suppl 2):S262-8. doi: 10.1111/j.1532-5415.2011.03674.x.
9
Pharmacokinetics and tolerability of intramuscular, oral and intravenous aripiprazole in healthy subjects and in patients with schizophrenia.
Clin Pharmacokinet. 2008;47(7):475-85. doi: 10.2165/00003088-200847070-00004.
10
Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit.
JAMA. 2004 Apr 14;291(14):1753-62. doi: 10.1001/jama.291.14.1753.
Zotero 插件